All In Biotech

Drug Trial Radar · NCT06228326

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs

Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Apr 17, 2024

Primary completion

Feb 2027

Study completion Jul 2028

Sponsor

Lead sponsor
Krystal Biotech, Inc.Industry
Sponsor type
Industry
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies. This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707. Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase. Combination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks. All subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.

Conditions

  • Lung Cancer, Non-small Cell
  • Lung Cancer Metastatic
  • Solid Tumor, Adult
  • Advanced Cancer
  • Lung Cancer (NSCLC)

Interventions

  • KB707Biological

    Genetically modified herpes simplex type 1 virus

  • Pembrolizumab (KEYTRUDA®)Drug

    PD-1 immune checkpoint inhibitor

  • ChemotherapyDrug

    SOC chemotherapy

  • DocetaxelDrug

    SOC chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)Time frame: up to 36 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • XCancer Research Network/Dothan Hematology & Oncology

    Dothan, Alabama · Recruiting

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • Precision NextGen Oncology

    Beverly Hills, California · Recruiting

  • Emad Ibrahim MD Inc

    Redlands, California · Recruiting

  • BRCR Global

    Weston, Florida · Recruiting

  • IU Simon Comprehensive Cancer Center

    Indianapolis, Indiana · Terminated

  • Ochsner/MD Anderson Cancer Center

    New Orleans, Louisiana · Recruiting

  • Henry Ford Health

    Detroit, Michigan · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Terminated

  • Sarah Cannon Research Institute

    Nasville, Tennessee · Recruiting

  • Renovatio Clinical

    El Paso, Texas · Terminated

  • Renovatio Clinical

    The Woodlands, Texas · Terminated

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.